To date, immunotherapies using PD-1/PD-L1 or CTLA-4 antagonistic antibodies have shown promising outcomes in various cancers such as melanoma, liver cancer and non-small cell lung cancer, thereby establishing immunotherapy as one of the most promising new therapeutic approaches (43–45). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.